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The patient is a chronically ill 8-year-old boy from Limpopo province in South Africa, living with 
his adoptive parents. He was born prematurely at 7 months’ gestation, weighing 1.9 kg. There 
was a history of recent travel to the Kruger National Park, and to India 6 months prior to admission. 
All his vaccinations were up to date on history, but this was never confirmed. He was markedly 
underweight for his age (with weight-for-age and height-for-age z scores of −2 and −1, respectively, 
and body mass index of 13) with a 2-year history of abdominal distension, diarrhoea, failure to 
thrive and drenching night sweats. There was no history of chronic cough. His treatment up to the 
time of admission included nutritional and iron supplements and repeated courses of antibiotics. 
No clinical improvement was achieved with this management.
The patient was referred to a paediatric gastroenterologist in October 2016. He was acutely ill, 
severely wasted (17 kg) and pyrexial (39 °C). He was clinically pale with a tachycardia and mild 
oedema of his lower limbs. Hepatosplenomegaly was detected, although there was no peripheral 
lymphadenopathy. His abdomen was severely distended, and he had recurrent diarrhoea and 
vomiting with marked intolerance of all foods.
Abdominal computed tomography (CT) scan and ultrasound revealed massively enlarged intra-
abdominal lymph nodes (see Figure 1) with a moth-eaten appearance of the spleen. Prominent 
collateral circulation was seen, which was suggestive of portal hypertension.
Laboratory investigations confirmed that the patient was HIV-infected with a CD4 count of 59 
cells/μL (7%) and HIV viral load of 453 780 copies/mL (log10 5.66). Further testing revealed mildly 
elevated liver enzymes. Moderate proteinuria was present and the faecal α-1 antitrypsin result 
was in keeping with a protein-losing enteropathy. His blood count showed microcytic hypochromic 
anaemia, with the iron function studies reflecting a pattern of reticuloendothelial iron blockade 
(see Table 1).
The differential diagnosis included tuberculosis or lymphoma. Over a period of 7 months, 
endoscopically and surgically obtained biopsy material was submitted for histology (see Table 2). 
Histological images of the duodenum and a lymph node are shown in Figure 2. The findings were 
consistent with non-tuberculous mycobacterial infection.
Further testing of the biopsy specimens included mycobacterial cultures, all of which showed no 
growth. Acid-fast bacilli (AFB) were noted during the processing of the tissue samples obtained 
from the intra-abdominal lymph nodes on 12 October 2016, and again in biopsy material obtained 
on 08 March 2017. Microscopy performed on a stool sample on 26 March 2017 also showed acid-
fast organisms with a coccoid appearance. The polymerase chain reaction (PCR) assay for 
Mycobacterium avium complex was negative (artus® Mycobac. diff. LC PCR from Qiagen, 
Germany). Numerous PCR assays for Mycobacterium tuberculosis complex were negative, which 
include Nanogen (Nanogen Inc., San Diego, CA, USA), BD MAX (BD Diagnostics, Sparks, MD) 
and the Xpert® MTB/RIF assay (Cepheid Inc., CA, USA). The urinary lipoarabinomannan test 
conducted on 22 March 2017 was positive.
This article presents a case of an HIV-infected paediatric patient with an unusual Mycobacterium 
genavense infection with predominantly abdominal organ involvement.
Keywords: Mycobacterium genavense; Non-tuberculous mycobacterium; 16S rRNA sequence 
analysis; Line-probe assay; Fastidious; Retractile mesenteritis.
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A cytomegalovirus (CMV) viraemia of 3974 copies/mL 
(log10 3.60) was measured in March 2017 together with a 
colon biopsy that was PCR positive for CMV. The Epstein 
Barr viral load at the time was 9318 copies/mL (log10 3.97).
Anti-mycobacterial treatment was started (rifampicin, 
isoniazid, ethambutol, pyrazinamide and clarithromycin) 
followed 4 weeks later with antiretroviral therapy (abacavir, 
lamivudine and efavirenz). The patient’s HIV viral load 
was undetectable at 3 months, and his CD4 count at that 
stage was 101 cells/μL (6%). Clinically and radiologically, 
however, there was no improvement in his abdominal signs 
and symptoms. Malabsorption and refeeding syndrome 
was considered, and all treatment, including ganciclovir, 
was given intravenously. His antiretroviral medication was 
temporarily suspended until oral feeding could be tolerated. 
Immune reconstitution inflammatory syndrome (IRIS) was 
considered, and methylprednisone was initiated (1 mg/kg/
dose) for 4 weeks, after which the dosage was tapered and 
stopped. The patient was given a period of bowel rest and 
free drainage, after which he was placed on an elemental 
diet. There was no clinical improvement and liver dysfunction 
worsened (see Table 1), and hence a decision was made to 
stop rifampicin, isoniazid and pyrazinamide.
In May 2017, a diagnosis of Mycobacterium genavense was 
made, based on sequencing of a mycobacterial 16S rRNA 
PCR product. This identity was subsequently confirmed 
using the HAIN Lifescience GenoType (Nehren, Germany) 
Mycobacterium AS assay that was performed directly on a 
histology specimen from May 2017. As a result of this finding, 
and in consultation with an infectious disease specialist 
and microbiologist, treatment was changed to include 
moxifloxacin, azithromycin and rifabutin for 2 years, with 
amikacin for the first 3 months. Methylprednisone was also 
restarted. Antiretroviral therapy, together with cotrimoxazole 
prophylaxis, was continued. 
The patient’s response to the new regimen was slow, and 
initially he was unable to tolerate food. Insertion of a 
nasogastric tube was required for continuous feeds together 
with total parenteral nutrition. At the time of writing this 
article (17 months of treatment completed), his clinical 
response had improved. He was able to tolerate small regular 
meals with no nausea, vomiting or diarrhoea. His weight 
gain had been slow (now up to 20 kg) despite nutritional 
supplementation. The hepatosplenomegaly and abdominal 
distension had improved markedly, and his HIV remains 
virologically suppressed.
Ethical consideration
Dr R. de Gama obtained consent from the patient’s parents to 
publish this case report.
TABLE 2: Histology results.
Date Biopsy material Histological findings
12 October 2016 Mesenteric  
lymphnode
Lymphadenitis; acid-fast bacilli (AFB) (short 
morphology); Periodic Acid Schiff (PAS) 
positive; poorly formed, focal granulomata 
Duodenum and  
caecum
Granulomatous duodenitis and colitis; 
histiocytes packed with acid-fast and PAS 
positive bacilli (small)
08 March 2017 Duodenum Duodenitis; weak epithelioid granuloma 
formation; histiocytes noted again as on 
previous biopsy material
Liver and intra- 
abdominal  
lymphnode
Liver: granulomatous hepatitis (moderate to 
well-formed epitheloid granulomata; scattered 
intracytoplasmic AFB in portal granulomata); 
intra-abdominal lymphnode: lymphadenitis; 
histiocytes filled with acid-fast and weakly PAS 
positive bacilli
06 May 2017 Duodenum The results were similar to previous biopsies, 
although the infiltrate of AFB containing 
histiocytes was less impressive in this specimen
TABLE 1: Laboratory results.
Biochemical/
haematological parameter
Patient value Reference range
October 2016 March 2017
ALP 91 IU/L 445 IU/L < 300 IU/L
GGT 58 IU/L 1098 IU/L < 17 IU/L
ALT 44 IU/L 92 IU/L < 39 IU/L
AST 84 IU/L 132 IU/L < 51 IU/L
Albumin 20 g/L - 38 g/L – 54 g/L
Globulin fraction 57 g/L - 22 g/L – 36 g/L
Urine protein:creatinine 
ratio
61 mg/mmol - < 20 mg/mmol
Faecal α-1 antitrypsin 1.72 mg/g - 0.43 mg/g – 1.47 mg/g
Haemoglobin 8.8 g/dL - 11.5 g/dL – 15.5 g/dL
MCV 75.6 fL - 77.0 fL – 95.0 fL
MCH 24.4 pg - 25.0 pg – 33.0 pg
Iron 6.2 mmol/L - 4.8 mmol/L – 17.2 mmol/L
Transferrin 1.5 g/L - 1.3 g/L – 3.1 g/L
Percentage saturation 17% - 17% – 42%
Ferritin 495 ng/mL - 7 ng/mL – 140 ng/mL
ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; MCV, mean corpuscular volume; MCH, mean corpuscular 
hemoglobin.
a b c
FIGURE 1: Radiology (computed tomography coronal images of the chest, abdomen and pelvis, a–c). Multiple conglomerate nodal masses are seen along the mesenteric, 
aorta, iliac and para-aortic nodal chains. There are also enlarged nodes in the porta hepatis. Several of the upper abdominal mesenteric nodes demonstrate low density, 
compatible with central necrosis. Diffuse hepatomegaly with no discrete lesion is seen.
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Discussion
The first case of M. genavense was described in 1987 in the 
clinical setting of acquired immunodeficiency syndrome 
(AIDS);1 the bacterium is closely related to Mycobacterium 
simiae.2 Mycobacterium genavense has been recovered from 
dogs, cats, rabbits, monkeys, ferrets and a variety of birds 
(parrots, budgerigars, amazons, flycatchers, zebra finches, 
hoopers, parakeets, parrotlets and waxwings).1,3 It is the most 
common cause of psittacine mycobacteriosis.4 It has also been 
isolated from the respiratory and gastrointestinal tracts of 
healthy individuals5,6 and from tap water.7 This organism has 
not been recovered from soil,8 and no human-to-human 
transmission has been described.9
Human isolates have been recovered from cultures of blood, 
bone marrow, liver, spleen and other tissues.8 Faeces may 
also show a large amount of AFB.4,9
Mycobacterium genavense is a fastidious non-tuberculous 
mycobacterium requiring special supplementation with 
mycobactin J, adjusted pH and incubation temperature 
of 37 °C – 45 °C for isolation from culture specimens.2,10 
Use of Middlebrook 7H11 solid medium supplemented 
with sheep blood and charcoal acidified to pH 6.2+/-0.2 
has also been noted.11 Thompson and colleagues12 used 
the BACTEC pyrazinamide test medium and determined 
pH 5.5 to yield the best growth for susceptibility testing. 
The duration of incubation is typically 8–12 weeks.8 
About 30% – 50% of cases are identified after prolonged 
incubation.10
Clinical presentation
Most clinical M. genavense isolates have been cultured from 
patients with advanced HIV infection, especially in the pre-
highly active antiretroviral therapy (HAART) era.9,10 
Mycobacterium genavense presents similarly to M. avium 
complex: It is encountered in patients with CD4 counts < 100 
cells/mm3; has a high affinity for the abdomen; and causes 
abdominal pain, diarrhoea, hepatosplenomegaly, lymph 
node enlargement and sometimes ascites.6 Mycobacterium 
genavense should be considered in HIV-infected patients with 
suspected disseminated M. avium complex, but whose 
routine cultures are negative.8 Immune reconstitution 
inflammatory syndrome may occur in patients on HAART 
infected with this pathogen, and symptoms may paradoxically 
worsen, leading to severe complications.6 Disseminated 
M. genavense infection account for 4% – 13% of non-
tuberculous mycobacteria in HIV-infected patients.13 
Descriptions of documented clinical cases with M. genavense 
in patients with HIV and/or AIDS have been similar to our 
patient in presentation and course of disease.
Recently, cases of M. genavense have been described in 
patients with non-HIV-related immunological pathology.10 
Risk categories in which clinical disease due to M. genavense 
occurs include patients with HIV and/or AIDS,4,5,6,13,14 
lymphoproliferative disorders,15,16 solid organ and allogeneic 
stem cell transplant patients,10,17,18,19 patients receiving chronic 
steroids in combination with other immunomodulating 
drugs20 and patients with primary immunodeficiency 
diseases.21,22,23
a b c
d e f
FIGURE 2: Histological images of the duodenum and lymphnode. (a) Histology of the duodenal mucosa showing lamina propria expansion by histiocyte sheets (hematoxylin 
and eosin, 100×). (b) Duodenal villus filled with abundant organism-containing histiocytes (hematoxylin and eosin, 400×). (c) Lymph node replaced by sheets of histiocytes 
with scattered intervening inflammatory cells (hematoxylin and eosin, 100×). (d) Lymph node histiocytes revealing finely granular to foamy cytoplasm, engorged with 
bacilli (hematoxylin and eosin, 400×). (e) Ziehl–Neelsen stain demonstrating large numbers of acid-fast bacilli in duodenal histiocytes (400×). (f) Periodic acid-Schiff stain 
showing granular positivity in the histiocyte intracytoplasmic organisms (400×).
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Other diseases that may be associated with M. genavense 
infection include sarcoidosis, hyper-IgE syndrome and auto-
immune disorders (systemic lupus erythematosus and 
myasthenia gravis).9,24,25,26,27
While most patients with M. genavense infection have 
immunological pathology, a case of disseminated M. genavense 
infection in a healthy Japanese boy has also been described. 
Computed tomography of the abdomen showed intestinal 
wall thickening from the ileocecum to the ascending colon, as 
well as small intestinal dilation and ascites. The only possible 
risk factor appeared to be exposure to pets, including dogs, 
rabbits, turtles and tropical fish.28
The clinical presentation of cases with M. genavense appears 
mostly to be disseminated involving abdominal organs. Less 
common presentations include pleuropulmonary, cutaneous, 
central nervous system and genital tract involvement.9,29 
Pulmonary involvement may include cavitations and 
reticular–nodular infiltrates on chest X-ray. A few cases of 
pulmonary M. genavense disease have been documented.20
The laboratory diagnosis of M. genavense infections usually 
relies on detection by molecular methods. Mycobacterial 16S 
rRNA sequence analysis is often used for the confirmation of 
the diagnosis.9,10 The GenoType Mycobacterium AS line 
probe assay (Hain Lifescience, Nehren, Germany) can also be 
used, but it cannot distinguish between M. genavense and 
Mycobacterium triplex. It is validated for use on cultured 
material. We ran this line-probe assay method directly on the 
duodenal biopsy according to the standard GenoType 
MTBDRplus protocol and were able to generate an 
interpretable banding pattern in our patient.
Treatment
In vitro susceptibility data are limited because of the 
extreme fastidiousness of the organism, requiring special 
supplementation, an acid pH and prolonged incubation.8,9 
Available data suggest that most isolates are susceptible 
to macrolides, rifamycins, fluoroquinolones and 
aminoglycosides (amikacin and streptomycin).8 Mycobacterium 
genavense is resistant to isoniazid.9 Optimal therapy is not 
determined.8 In animal models, a reduction in AFB burden is 
seen after 15–30 days with clarithromycin and rifampicin and 
after 30 days with amikacin and ethambutol.10 A three- or 
four-drug regimen is typically suggested. In one case series, 
a regimen including a macrolide, ethambutol and often 
rifampicin recorded a favourable outcome in 75% of cases 
(9/12).20 In another case series, the survival rate at 1 year was 
72%. In this case series, a treatment regime typically included 
clarithromycin, ethambutol and rifabutin, and sometimes 
also a fluoroquinolone or amikacin.27
Multidrug therapies that include clarithromycin appear 
to be more effective than those without clarithromycin.8 
Ethambutol, despite limited in vitro activity against 
M. genavense,8,12 is included in treatment regimens of many 
documented cases of M. genavense infections.20,27 In our 
patient, ethambutol was given for a total of 10 months as part 
of the initial treatment. Older literature refers to the use of 
clofazimine.30,31,32 This drug was used less frequently for the 
treatment of disseminated non-tuberculous mycobacterial 
disease after a clinical study found that clofazimine in 
combination with clarithromycin and ethambutol was 
associated with increased mortality in disseminated M. avium 
complex infections in patients with AIDS.33 The use of 
prednisone has been advocated to reduce local inflammation 
and compressive effects of the affected organs. In one study, 
it was used for 10 months.6 A case series where steroid 
therapy was included did not describe worse outcomes.27
Treatment duration and follow-up
The documented cases of M. genavense disease indicate that the 
duration of treatment should be prolonged to more than 12–27 
months.10,21 To make recommendations on the termination of 
treatment for these cases is therefore challenging. Due to the 
fastidious nature of the mycobacterium, treating cases until 
12 months culture negativity8 is problematic and treating for as 
long as the immunodeficiency is present has resulted in life-
long treatment in some patients.20 Mycobacterial blood culture 
(with prolonged incubation) and stool AFB where appropriate 
may be of value as markers of treatment response.
Follow-up radiological investigation, especially if CT is used, 
increases the risks associated with radiation exposure. Some 
authors suggest an X-ray and high-resolution CT at baseline 
prior to the commencement of therapy.34 Follow-up radiology 
should be considered together with clinical assessment.34 
Follow-up with repeat biopsies from the affected organs 
to compare with initial histology reports might be another 
option6; although as granulomas persist much longer than the 
infection/disease, this might be a poor marker of response. 
Rebiopsy for histology and culture may be considered when 
treatment failure is suspected. 
Complications
A poorly understood pathogen-specific syndrome similar to 
retractile mesenteritis has been described in patients infected 
with M. genavense where chronic fibrosing inflammation is 
found in the small bowel mesentery. Rarely, chylous ascites 
may develop.4,6 Persistent relapsing infection may occur in 
patients with profound immunosuppression and high HIV 
viral loads at initial diagnosis with a large inoculum of 
M. genavense organisms.6 A case of an HIV-infected paediatric 
patient with intestinal lymphangiectasia and protein-losing 
enteropathy has been described. This patient presented 
with severe hypogammaglobulinaemia and moderate 
hypoalbuminaemia. Lymphatic vessel dilatation, small 
intestinal wall thickening, ascites as well as retroperitoneal 
and mesenteric adenopathy were seen on abdominal 
magnetic resonance imaging. Elevated α-1 antitrypsin in 
stool confirmed the diagnosis of protein-losing enteropathy.13 
A similar scenario was reported by Tassone and colleagues.21 
Hyperammonemia was described in a renal transplant case 
with disseminated M. genavense infection.35
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Conclusion
The patient described in this case report is illustrative of 
the difficulties encountered in accurately diagnosing and 
managing disease caused by non-tuberculous mycobacteria, 
in this case M. genavense. Clinicians and laboratory 
professionals need to be aware of non-tuberculous 
mycobacterial infections, particularly encountered in 
immunocompromised patients and use available molecular 
diagnostic tools to obtain a diagnosis.
Teaching points
• Mycobacterium genavense should be considered in HIV-
infected patients with suspected disseminated M. avium 
complex, but whose routine cultures are negative.
• This organism is the most common cause of psittacine 
mycobacteriosis.
• The clinical presentation of patients with M. genavense 
usually includes dissemination involving abdominal 
organs.
• Available molecular diagnostic tools are used to obtain a 
diagnosis.
• A three- or four-drug regimen is typically suggested for 
treatment.
• Treatment is prolonged to more than 12–27 months.
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